Published in Curr Psychiatry Rep on October 01, 2006
Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol (2010) 1.71
mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology (2008) 1.57
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev (2008) 1.26
Modafinil and memory: effects of modafinil on Morris water maze learning and Pavlovian fear conditioning. Behav Neurosci (2009) 1.21
Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse. Psychopharmacology (Berl) (2010) 1.19
Forced abstinence model of relapse to study pharmacological treatments of substance use disorder. Curr Drug Abuse Rev (2009) 1.11
How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving: Craving and ongoing methamphetamine use. Subst Abuse (2009) 1.02
Bupropion attenuates methamphetamine self-administration in adult male rats. Drug Alcohol Depend (2008) 1.00
Methamphetamine: here we go again? Addict Behav (2011) 0.95
Bupropion differentially impacts acquisition of methamphetamine self-administration and sucrose-maintained behavior. Pharmacol Biochem Behav (2008) 0.95
Extinction-dependent alterations in corticostriatal mGluR2/3 and mGluR7 receptors following chronic methamphetamine self-administration in rats. PLoS One (2012) 0.91
Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J Food Drug Anal (2013) 0.89
Current research on methamphetamine: epidemiology, medical and psychiatric effects, treatment, and harm reduction efforts. Addict Health (2015) 0.88
Novel medications to treat addictive disorders. Curr Psychiatry Rep (2008) 0.85
Chronic modafinil effects on drug-seeking following methamphetamine self-administration in rats. Int J Neuropsychopharmacol (2011) 0.84
Effect of Exercise Training on Striatal Dopamine D2/D3 Receptors in Methamphetamine Users during Behavioral Treatment. Neuropsychopharmacology (2015) 0.83
Pharmacological strategies for detoxification. Br J Clin Pharmacol (2014) 0.82
Modafinil restores methamphetamine induced object-in-place memory deficits in rats independent of glutamate N-methyl-D-aspartate receptor expression. Drug Alcohol Depend (2013) 0.81
Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug Alcohol Depend (2016) 0.76
Relapse and Risk-taking among Iranian Methamphetamine Abusers Undergoing Matrix Treatment Model. Addict Health (2016) 0.75
More alike than different: health needs, services utilization, and outcomes of Asian American and Pacific Islander (AAPI) populations treated for substance use disorders. J Ethn Subst Abuse (2012) 0.75
Chronic methamphetamine self-administration disrupts cortical control of cognition. Neurosci Biobehav Rev (2016) 0.75
Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med (2003) 6.94
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (2011) 6.35
Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci (2004) 4.14
A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction (2005) 4.14
Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). Addiction (2008) 3.98
The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs (2003) 3.91
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry (2011) 3.15
Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry (2004) 3.02
DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry (2013) 2.89
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict (2004) 2.85
A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry (2002) 2.64
Smoking cessation in methadone maintenance. Addiction (2002) 2.62
Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology (2007) 2.42
A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction (2006) 2.30
Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction (2013) 2.23
Medications development: successes and challenges. Pharmacol Ther (2005) 1.80
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr (2014) 1.79
Treatment for amphetamine withdrawal. Cochrane Database Syst Rev (2009) 1.75
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend (2008) 1.73
A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. Contemp Clin Trials (2010) 1.72
Substance abuse among Iranian high school students. Curr Opin Psychiatry (2010) 1.72
Will the methamphetamine problem go away? J Addict Dis (2002) 1.67
Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis (2002) 1.63
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction (2013) 1.63
Evidence-based practices in addiction treatment: review and recommendations for public policy. Health Policy (2010) 1.61
Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction (2012) 1.59
Naltrexone and dysphoria: fact or myth? Am J Addict (2002) 1.56
Treatment responsivity of cocaine-dependent patients with antisocial personality disorder to cognitive-behavioral and contingency management interventions. J Consult Clin Psychol (2003) 1.51
A 12-year follow-up of a treated cocaine-dependent sample. J Subst Abuse Treat (2006) 1.50
The relationship between methamphetamine use and increased dental disease. J Am Dent Assoc (2010) 1.49
Methamphetamine abstinence syndrome: preliminary findings. Am J Addict (2004) 1.49
Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend (2006) 1.47
A comparison of patterns of methamphetamine and cocaine use. J Addict Dis (2002) 1.45
Application of syndemic theory to black men who have sex with men in the Multicenter AIDS Cohort Study. J Urban Health (2012) 1.44
Opiate recidivism in a drug-treatment program: comparison of hair and urine data. J Anal Toxicol (2003) 1.43
Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend (2010) 1.41
Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry (2005) 1.40
Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction (2013) 1.39
Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend (2011) 1.38
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend (2012) 1.37
Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis (2009) 1.37
Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry (2003) 1.36
Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse (2011) 1.29
Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction (2010) 1.27
Contingency management: schedule effects. Psychiatry Res (2006) 1.22
Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs (2013) 1.22
Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs? J Subst Abuse Treat (2010) 1.21
The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat (2004) 1.19
Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. Addiction (2002) 1.18
Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry (2011) 1.16
Long-term course of opioid addiction. Harv Rev Psychiatry (2015) 1.14
Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis (2002) 1.13
Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. J Addict Dis (2007) 1.13
A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med (2013) 1.11
Capacity building and collaborative research on cross-national studies in the Asian region. J Food Drug Anal (2013) 1.11
Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. Int J Neuropsychopharmacol (2008) 1.11
Conducting clinical research with prescription opioid dependence: defining the population. Am J Addict (2010) 1.10
Traditional medicine in the treatment of drug addiction. Am J Drug Alcohol Abuse (2009) 1.09
Factors associated with event-level stimulant use during sex in a sample of older, low-income men who have sex with men in Los Angeles. Drug Alcohol Depend (2009) 1.07
Sexual risk trajectories among MSM in the United States: implications for pre-exposure prophylaxis delivery. J Acquir Immune Defic Syndr (2014) 1.07
Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug Alcohol Depend (2008) 1.07
Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat (2008) 1.05
Risk factors for suicide attempts in methamphetamine-dependent patients. Am J Addict (2008) 1.04
Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network. J Psychiatr Res (2011) 1.04
Gender differences in prevalence of drug use among high risk adolescents in Israel. Addict Behav (2005) 1.04
Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. Clin Neurophysiol (2004) 1.03
Adoption of drug avoidance activities among patients in contingency management and cognitive-behavioral treatments. J Subst Abuse Treat (2002) 1.02
Hepatitis C virus infection, substance use and mental illness among homeless youth: a review. AIDS (2005) 1.01
Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend (2009) 1.00
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs (2014) 1.00
Changes in stimulant drug use over time in the MACS: evidence for resilience against stimulant drug use among men who have sex with men. AIDS Behav (2012) 0.99
Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network. J Subst Abuse Treat (2010) 0.99
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am J Manag Care (2011) 0.99
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend (2006) 0.99
Optimizing smoking cessation outcomes among the methadone maintained. J Subst Abuse Treat (2002) 0.99
Stimulant use among African American and Latino MSM social networking users. J Addict Dis (2013) 0.98
Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network. Subst Abuse Rehabil (2010) 0.98
Childhood adverse events and methamphetamine use among men and women. J Psychoactive Drugs (2008) 0.97
Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. Drug Alcohol Depend (2005) 0.97
Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. Addict Behav (2003) 0.97
Diffusion of substance abuse treatment: will buprenorphine be a success? J Psychoactive Drugs (2004) 0.97
Dancing with strangers: will U.S. substance abuse practice and research organizations build mutually productive relationships? Addict Behav (2002) 0.96
Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. Subst Use Misuse (2011) 0.95
Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction (2005) 0.95
Integration of substance use disorder services with primary care: health center surveys and qualitative interviews. Subst Abuse Treat Prev Policy (2014) 0.94
Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J Addict Dis (2002) 0.94
Predictors of outcome after short-term stabilization with buprenorphine. J Subst Abuse Treat (2012) 0.94
Comparing buprenorphine induction experience with heroin and prescription opioid users. J Subst Abuse Treat (2012) 0.93
Facilitating the adoption of contingency management for the treatment of substance use disorders. Behav Anal Pract (2009) 0.92
Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clin Neurophysiol (2003) 0.92
Gabapentin improves cold-pressor pain responses in methadone-maintained patients. Drug Alcohol Depend (2010) 0.92
An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology (2013) 0.92
Participant characteristics and buprenorphine dose. Am J Drug Alcohol Abuse (2011) 0.91
Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning. Am J Addict (2010) 0.91
Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study. AIDS (2015) 0.91